CGT Catapult names new CEO

Mathew Durdy has been appointed as CEO to lead the Cell and Gene Therapy Catapult as the organisation prepares to accelerate innovation, growth and productivity in the UK.

Durdy, who currently serves as the organisation’s Chief Business Officer, was part of the 2012 team that created the CGT Catapult. He replaces founder CEO Keith Thompson who is retiring in the spring.

“There is so much that we can do that will accelerate the growth of this industry which creates high value jobs in the UK, and at the same time brings life changing treatments to children, cancer sufferers, and many others with currently unmet acute and chronic healthcare needs,” he said.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news